XELOX + Bevacizumab compared to FOLFOX4 + Bevacizumab in First line Metastatic Colorectal Cancer in a Non-reimbursed Health Care System: A Cost Analysis

Authors

  • Jerry Y. Tan Chun Bing
  • Andrew A. Yacat
  • Dennis L. Sacdalan

DOI:

https://doi.org/10.47895/amp.v49i2.988

Abstract

...

Downloads

Published

2015-06-30

Issue

Vol. 49 No. 2 (2015)

Section

Articles

How to Cite

1.
XELOX + Bevacizumab compared to FOLFOX4 + Bevacizumab in First line Metastatic Colorectal Cancer in a Non-reimbursed Health Care System: A Cost Analysis. Acta Med Philipp [Internet]. 2015 Jun. 30 [cited 2025 Apr. 5];49(2). Available from: https://actamedicaphilippina.upm.edu.ph/index.php/acta/article/view/988

Most read articles by the same author(s)